Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib-Reference-Cited by-同舟云学术

Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Published:2018-11-01 Issue:11 Volume:4 Page:1527
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Oxnard Geoffrey R.¹²,Hu Yuebi¹,Mileham Kathryn F.³,Husain Hatim⁴,Costa Daniel B.⁵,Tracy Philip¹⁶,Feeney Nora⁷,Sholl Lynette M.⁸,Dahlberg Suzanne E.¹,Redig Amanda J.¹²,Kwiatkowski David J.¹²,Rabin Michael S.¹²,Paweletz Cloud P.⁷,Thress Kenneth S.⁹,Jänne Pasi A.¹²⁷

Affiliation:

1. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

2. Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

3. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina

4. Moores Cancer Center, University of California San Diego, La Jolla

5. Beth Israel Deaconess Medical Center, Boston, Massachusetts

6. Medical student, Tufts University School of Medicine, Boston, Massachusetts

7. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts

8. Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts

9. Translational Sciences, Oncology IMED Biotech Unit, AstraZeneca, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference38 articles.

1. AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer.;Jänne;N Engl J Med,2015

2. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.;Mok;N Engl J Med,2017

3. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.;Oxnard;J Clin Oncol,2015

4. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer.;Soria;N Engl J Med,2018

5. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.;Ou;Lung Cancer,2016

Cited by 553 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Supramolecular self-assembly strategy for the enhanced solubility/dissolution rate and anti-cancer efficacy of osimertinib: Insights from multi-component crystals to drug chemistry;Chemical Engineering Science;2024-11

2. Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer;Nature Communications;2024-09-09

3. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development;Cancer Treatment Reviews;2024-09

4. Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC;ESMO Real World Data and Digital Oncology;2024-09

5. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24